Ketol-acid reductoisomerase: An important antituberculosis drug target [ 2018 - ]

Research Grant

Researchers: A/Pr Luke Guddat (Principal investigator) ,  A/Pr Ross McGeary ,  Dr Nicholas West ,  Prof Gerhard Schenk

Brief description Due to the increasing prevalence of drug resistance, new antituberculosis medications are urgently needed. Here, we will use rational structure-based approaches to design new inhibitors of ketolacid reductoisomerase (KARI), an enzyme whose activity is essential to the survival of this pathogen that resides in the lungs of humans. These inhibitors will be converted into prodrug formulations for optimal activity in cell-based assays and in mice infected with this pathogen.

Funding Amount $680,585.00

Funding Scheme Project Grants

Notes Standard Project Grant